Tech Company Financing Transactions
Kimia Therapeutics Funding Round
Kimia Therapeutics secured a $55 million Series A funding round on 12/19/2023. Investors included Dimension, The Column Group and Horizons Ventures.
Transaction Overview
Company Name
Announced On
12/19/2023
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series A
Investors
Proceeds Purpose
The funding will enable Kimia to expand its ATLAS platform and pursue a broad range of therapeutic targets in oncology, immunology and inflammation while continuing to partner with Carmot Therapeutics Inc. (Carmot) on key metabolic programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
740 Heinz Avenue
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Undisclosed
Website
Email Address
Overview
Developer of a drug discovery platform intended to cater to the areas of oncology, immunology, and inflammation. The company's platform helps apply high throughput precision chemistry in combination with genome editing and machine learning to identify druggable sites at key nodes of intervention in human disease and to generate datasets that reveal the molecular features of active and inactive drug molecules and through machine learning generate algorithms and feature maps, helping clients accelerate the discovery of drugs for novel and challenging targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stig Hansen
Browse more venture capital transactions:
Prev: 12/19/2023: Iris&Romeo venture capital transaction
Next: 12/19/2023: NewLeaf Symbiotics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs